Oseltamivir and early deterioration leading to death: a proportional mortality study for 2009A/H1N1 influenza
- PMID: 22156085
- DOI: 10.3233/JRS-2011-0545
Oseltamivir and early deterioration leading to death: a proportional mortality study for 2009A/H1N1 influenza
Abstract
Objective: To examine the epidemiological association between sudden deterioration leading to death and Tamiflu use.
Design: Proportional mortality study.
Setting: Japan.
Participants: 162 deaths without deterioration before the first consultation among all 198 deaths of mostly confirmed 2009A/H1N1 influenza. POPULATION AT RISK: Age-specific population of influenza patients prescribed Tamiflu and Relenza.
Main outcome measure: Age-stratified pooled odds ratio (OR) for early (within 12 hours) deterioration and overall death of Tamiflu prescribed to Relenza prescribed patients.
Results: Of 119 deaths after Tamiflu was prescribed, 38 deteriorated within 12 hours (28 within 6 hours), while of 15 deaths after Relenza, none deteriorated within 12 hours. Pooled OR for early deterioration and overall death were 5.88 (95% CI: 1.30 to 26.6, p = 0.014) and 1.91 (p = 0.031) respectively. Baseline characteristics including risk factors did not contribute to early deterioration after Tamiflu use.
Conclusions: These data suggest Tamiflu use could induce sudden deterioration leading to death especially within 12 hours of prescription. These findings are consistent with sudden deaths observed in a series of animal toxicity studies, several reported case series and the results of prospective cohort studies. From "the precautionary principle" the potential harm of Tamiflu should be taken into account and further detailed studies should be conducted.
Similar articles
-
Is oseltamivir (Tamiflu) safe? Re-examining the Tamiflu 'ado' from Japan.Expert Rev Pharmacoecon Outcomes Res. 2010 Feb;10(1):17-24. doi: 10.1586/erp.09.70. Expert Rev Pharmacoecon Outcomes Res. 2010. PMID: 20121561 Review.
-
[New influenza A (H1N1): advised indication and prescription of antiviral drugs].Ned Tijdschr Geneeskd. 2009;153:A1053. Ned Tijdschr Geneeskd. 2009. PMID: 19857317 Dutch.
-
Clinical effectiveness of oseltamivir and zanamivir for treatment of influenza A virus subtype H1N1 with the H274Y mutation: a Japanese, multicenter study of the 2007-2008 and 2008-2009 influenza seasons.Clin Infect Dis. 2009 Dec 15;49(12):1828-35. doi: 10.1086/648424. Clin Infect Dis. 2009. PMID: 19911968
-
Comparison of the effectiveness of Zanamivir and Oseltamivir against influenza A/H1N1, A/H3N2, and B.Clin Infect Dis. 2009 Apr 1;48(7):996-7. doi: 10.1086/597360. Clin Infect Dis. 2009. PMID: 19260819 No abstract available.
-
The use of antiviral agents for the management of severe influenza.Crit Care Med. 2010 Apr;38(4 Suppl):e43-51. doi: 10.1097/CCM.0b013e3181c85229. Crit Care Med. 2010. PMID: 19935416 Review.
Cited by
-
The mechanisms of delayed onset type adverse reactions to oseltamivir.Infect Dis (Lond). 2016 Sep;48(9):651-60. doi: 10.1080/23744235.2016.1189592. Epub 2016 Jun 2. Infect Dis (Lond). 2016. PMID: 27251370 Free PMC article.
-
Progress of Influenza Viruses and Inhibitors.Curr Med Chem. 2025;32(20):4055-4077. doi: 10.2174/0109298673268314231204061224. Curr Med Chem. 2025. PMID: 38362681 Review.
-
Neuraminidase inhibitors for preventing and treating influenza in adults and children.Cochrane Database Syst Rev. 2014 Apr 10;2014(4):CD008965. doi: 10.1002/14651858.CD008965.pub4. Cochrane Database Syst Rev. 2014. PMID: 24718923 Free PMC article.
-
The Development History, Structural Composition, and Functions of Influenza Viruses and the Progress of Influenza Virus Inhibitors in Clinics and Clinical Trials.Mini Rev Med Chem. 2025;25(3):196-207. doi: 10.2174/0113895575316416240724043949. Mini Rev Med Chem. 2025. PMID: 39113298 Review.
-
Efficacy and safety of Chou-Ling-Dan granules in the treatment of seasonal influenza via combining Western and traditional Chinese medicine: protocol for a multicentre, randomised controlled clinical trial.BMJ Open. 2019 Apr 2;9(4):e024800. doi: 10.1136/bmjopen-2018-024800. BMJ Open. 2019. PMID: 30944133 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical